OMLYCLO

GrowthmAb

omalizumab-igec

BLAINJECTIONINJECTABLE

Approved

Mar 2025

Lifecycle

Growth

Competitive Pressure

30/100

Clinical Trials

1

Clinical Trials (1)

NCT07425639N/ARecruiting

ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar

Started Oct 2025

225 enrolled

Chronic Spontaneous Urticaria (CSU)Allergic Asthma

Company

Korea - Incheon

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers